In the Original Investigation titled “Association of O⁶-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer,”¹ the authors had failed to provide citations to and description of the previously published and related 9 studies; a more complete explanation of the role of Shanghai Outdo Biotech Co, Ltd, in creating the tissue microarrays and evaluating the immunohistochemistry scores; and a better explanation of the rationale for use of R software, version 3.3.2, in the Abstract, Introduction, Methods, and eMethods 1 and eMethods 2 in the Supplement. These omissions did not affect the conclusions of the article. A Letter of Explanation² has been published that details the source of these errors. This article has been corrected online.

在题为“O ^{6 -甲基鸟嘌呤-DNA 甲基转移酶蛋白表达与 II 期或 III期}胃癌患者术后预后和辅助化疗益处的关联” 1的原始调查中，作者未能提供对先前研究的引用和描述。已发表及相关的 9 项研究；更完整地解释了上海奥多生物技术有限公司在创建组织微阵列和评估免疫组织化学评分中的作用；以及补充材料的摘要、引言、方法和 eMethods 1 和 eMethods 2 中对使用 R 软件 3.3.2 版的基本原理的更好解释。这些遗漏并不影响文章的结论。解释信²已发布详细说明这些错误的来源。本文已在线更正。